Stimulation of Multiple Organoids Simultaneously

Projektinformationen

STIMOS

ID Finanzhilfevereinbarung: 842804

DOI

10.3030/842804

Projekt abgeschlossen

EK-Unterschriftsdatum 12 April 2019

Startdatum 2 September 2019

Enddatum 1 September 2021

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten

€ 203 149,44

EU-Beitrag

€ 203 149,44

Koordiniert durch

MAXWELL BIOSYSTEMS AG
Switzerland

Periodic Reporting for period 1 - STIMOS (Stimulation of Multiple Organoids Simultaneously)

Berichtszeitraum: 2019-09-02 bis 2021-09-01

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Visual impairment affects approximately 26 million Europeans (WHO 2010): 2.5 million of these people are blind and 23.8 million have reduced vision. In France, Germany, Italy, and the UK the estimated cost for treatment is €47 billion per year. To date the majority of efficacy and safety testing in ophthalmological drug development is performed on animal models (rodents and rabbits), while these provide significant insight, they fall short of accurately modelling the complex structure of the human retina. With significant scientific advances in generation of in vitro human retinas by stem cell technology and industrial interest for vision restoration, STIMOS project aims to develop a system for simultaneous light stimulation of multiple retinal samples. STIMOS will be used in combination with MaxTwo, a multi-well high-resolution MEA platform for drug testing and sample functional studies, in order to test preclinical visual restoration techniques. STIMOS project enabled the grantee to transition from academic environment to industry. Within the STIMOS project, the grantee used his scientific and technical skills to develop a product prototype, which can be commercially exploited by MaxWell Biosystems.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The main worked performed during STIMOS project includes:
- A market study on light stimulation modules for use with microelectrode arrays.
- Development and testing of fully customizable stimulation hardware and software capable of inducing light mediated electrical activity in retina and 3D human retinal organoids.
- A tissue holder suitable for multi-well microelectrode array application.
- A multi-well LED based stimulation device, packaged in a multi-well platform compatible format.
MaxWell Biosystems is currently integrating the STIMOS prototype into a perfusion system.
MaxWell Biosystems is currently performing a customer survey, in order to learn how many laboratories plan to adopt STIMOS platform in the next 2 years.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

In the past two decades, mice have been extensively used to study the mammalian visual system and as models of human retinal diseases, due to the availability of transgenic mouse lines that enabled labeling and manipulation of genetically-defined neuronal populations. The availability of functional human retinal organoids for studying cell types, neural circuits and mechanisms of vision opened new frontiers to model and find cures for human eye diseases.
STIMOS platform can record and identify retinal ganglion cell mosaics in a high throughput per well (>1000 RGCs per well). HD-MEA technology featured in STIMOS platform is particularly suited for recording retinal output due to (1) full accessibility of all neurons, (2) electrodes with the largest spike amplitude can be chosen for spike extraction (3) each neuron will have unique action potential spatial profile or distribution. STIMOS allows to classify retinal ganglion cell electrophysiological activity in human retinal organoids. Importantly, STIMOS enables scientists to test effectiveness of therapies for blindness and assess their of functionality in distinct classes of retinal ganglion cells types. Furthermore, STIMOS delivers accurate and multiparametric new datasets for machine learning and advanced algorithms. Long-term, this approach will allow to test and assess personalized eye therapies for vision diseases.

stimos.jpg